CMS TESTS AI PAYMENT MODEL WITH 150 TECH FIRMS

The Centers for Medicare & Medicaid Services (CMS) is launching a pilot program called ACCESS to test a new reimbursement model for artificial intelligence applications in healthcare. The initiative involves 150 technology companies and represents a significant shift in how Medicare may pay for AI-assisted medical services. Under traditional Medicare payment structures, providers receive compensation based on the volume of services delivered. ACCESS instead ties payment directly to health outcomes, creating financial incentives for AI developers and healthcare providers to prioritize patient results. The outcome-based approach addresses longstanding concerns about healthcare spending efficiency. By aligning payment with measurable outcomes, CMS aims to encourage innovation while controlling costs. Companies participating in the pilot must demonstrate that their AI solutions improve patient health, reduce hospitalizations, or achieve other measurable clinical improvements. The 150-company participant pool suggests broad industry engagement, ranging from established healthcare IT vendors to emerging AI startups. The diversity of participants indicates CMS's intent to test various AI applications across different medical specialties and care settings. This pilot carries significant implications for healthcare technology investment. Success could accelerate AI adoption in Medicare, while establishing ACCESS as a replicable model for other government health programs. The outcome-based framework may also influence how private insurers structure AI reimbursement. CMS has previously explored alternative payment models through programs like the Centers for Medicare & Medicaid Innovation (CMMI). However, explicitly designing a reimbursement system around AI-driven care represents a notable evolution in how the agency approaches healthcare technology. The ACCESS program underscores growing recognition that AI deployment in healthcare requires appropriate financial incentives. As clinicians increasingly use AI tools for diagnostics, treatment planning, and patient monitoring, payment structures must evolve to reward genuine clinical value rather than simply processing volume. Details about the pilot's duration, specific outcome metrics, and participant selection criteria have not been fully disclosed. The program's success will likely influence federal policy regarding AI reimbursement across Medicare and other government healthcare programs.